Snapshot date: 2026-10-18 · Built: 2026-10-19T15:24:33+00:00 · Publication status: PASS

COMPANY RESEARCH

Convatec Group Plc

CTEC.L · United Kingdom · Healthcare · Medical Instruments & Supplies

INSIDER SIGNAL

Insider activity score：59.9 / 100

4 insiders · 4 purchase events · €379k net purchases

Europe #307 · United Kingdom #89

WHY THIS SIGNAL?

Score anatomy

Each bar shows the contribution to the current score; the weights and formula stay unchanged.

Cluster+21.0 / 35

How many distinct insiders bought in the cluster

Purchase size+20.8 / 25

Purchase value relative to company size and liquidity

Role+20.0 / 20

The seniority and relevance of participating insiders

Recency+8.1 / 10

How recently the purchases occurred

Conviction+10.0 / 10

How clearly buying stands out from other activity

What is holding the score back?

⚠ Buyer breadth is moderate · fewer than 4 distinct filers
✓ Strong insider role · ceo/chair involved
✓ Recent activity · latest purchase 2026-10-14

The role contribution uses the inverted role input of the current European model.

BUYING PROFILE

4 events · 4 insiders · 180d

Cluster 50%Repeat 0%Independent 50%Large 0%

Percentages are mutually exclusive and sum to 100%.

Buying concentration

35%

Largest buyer：Tobias Hestler · 113k GBP
Gross qualified purchase transaction-line value：320k GBP

The headline € total is net buying for the screen; this module uses gross qualified purchase transaction-line values in the filing currency, so the amounts can differ. The current 15-day buyer-breadth input counts distinct buyers; value concentration is disclosed separately here.

This is a ranking under the current European screening rules—not a probability of gain, return forecast, or buy recommendation.

Key purchase quotes (filing currency)

Filer	Price per unit	Trade date
Jens Viebke	2.298 GBP	Oct 14, 2026
Tobias Hestler	2.258 GBP	Aug 7, 2026
Jonny Mason	2.01169 GBP	May 27, 2026

Model details

Cluster breakdown (does not change the score)

15-day buyer breadth (count): 2 distinct reported filers
Peak time window: 2026-05-27 to 2026-05-27
Current breadth input: 0.600 (capped at 4+ buyers)
Buyer independence: Not yet measured; related-party fields are not cross-market comparable

What the filings show

🟢 Recent eligible purchase
Jens Viebke · 56k GBP · Price 2.298 GBP · Oct 14, 2026
🟢 PDMR purchase
Tobias Hestler · 113k GBP · Price 2.258 GBP · Aug 7, 2026
🟢 PDMR purchase
Jonny Mason · 101k GBP · Price 2.01169 GBP · May 27, 2026
🟡 1 remaining qualified transaction line(s) across 1 disclosure(s)

Insider vs stock price

3 purchase day(s), 4 purchase line(s) in the 180-day window.

Daily close (GBp)Day with an insider purchaseTwo or more insiders the same day

Markers sit on the closing price of the transaction day. They show when insiders traded, not the price they paid or received. "Since" compares that day's close with the last close shown; it is what happened at this company, not a forecast.

If you had followed the purchase

Each row starts on the first close on or after the day a purchase was made public, the earliest a reader could have acted, and ends on the last close shown above.

Amount put in (GBp)

Made public	Insiders	In this stock, now	In the median peer stock, now	Difference
2026-05-27	2	86,343 +8534.3%	1,004 +0.4%	+85,338 +8533.8 pts
2026-08-07	1	75,113 +7411.3%	975 −2.5%	+74,138 +7413.8 pts
2026-10-14	1	1,014 +1.4%	1,000 +0.0%	+14 +1.4 pts

3 of 3 disclosure day(s) ended ahead of the median peer stock.

Close to close, before costs, taxes, dividends and currency moves. The peer is the median of the other stocks on the same exchange for which this site holds prices (84 here), not an index. This is what happened, not a forecast: across all purchases on this site the typical gap is close to zero.

Insider timeline

2 insiders bought on the same day, 27 May: 1 CFO, 1 CEO / chair. 2 more bought afterwards. The share closed at 2.76 that day and at 238.00 most recently (+8534.3%). That week 237 companies across Europe disclosed insider purchases, more than in 81% of the last 26 weeks: insiders often buy together when a closed period ends, so the timing alone says less than it seems.

Tap an item for what it means.

●A purchase: the bigger the dot, the more was bought

Each dot is one insider's purchases on one day. The dot's area follows the amount: the largest purchase here gets the largest dot. Hold the pointer over a dot to see the date and the amount.

▮Purple band: several insiders bought within 15 days

The band marks the stretch with the most different buyers: at most 15 days long and at least two people. Here it is 27 May, with 2 insiders. Only the strongest stretch is marked. Several people deciding the same thing is harder to explain by one person's private reasons, but insiders often buy together just after a closed period ends, so compare it with the grey weekly bars.

Blue line: this share's price, +7514.0% over these six months

The closing price of each day, from 3.13 on 2026-04-21 to 238.00 on 2026-10-16. The line has no scale; read it for high and low: a dot on a low stretch was bought cheaply, a dot on a high stretch was not.

Dashed line: the typical stock on the same exchange, +2.7%

Taken from the 491 other stocks on the same exchange that this site holds prices for. Each is measured from the first day of the window, and every day the middle one is drawn. It starts where the blue line starts, so the gap between the two is the difference: this share +7514.0%, the typical one +2.7%, 7511.3 points ahead. It is not an index and not a comparison within one industry.

▂Grey bars: companies across Europe disclosing purchases each week

A taller bar is a week in which more companies disclosed insider purchases. The purple bar is the week of the band above: 237 companies, number 4 of the last 26 weeks. If that week was a peak anyway, buying together is less special than it looks.

This company: insiders buying per month, last 12 months

Nov

Dec

Jan

Feb

Mar

Apr

2May

Jun

Jul

1Aug

Sep

1Oct

Darker bars are inside the 180-day window above.

Who traded

Insider	Role	Purchases	Sales	Bought	First purchase	Share price since	Earlier purchases
Fiona Ryder	CFO	1	—	50.0k GBP	2026-05-27	+8534.3%	fewer than 5 completed
Jonny Mason	CEO / chair	1	—	100.6k GBP	2026-05-27	+8534.3%	fewer than 5 completed
Tobias Hestler	Board member	1	—	112.9k GBP	2026-08-07	+7411.3%	fewer than 5 completed
Jens Viebke	Board member	1	—	56.1k GBP	2026-10-14	+1.4%	fewer than 5 completed

Why this score? · Model details

Priority = 100 × Σ(fixed weight × 0–1 rule-based input)

Factor	Weight	This company input	Point contribution
15-day buyer breadth (count)	35%	0.600	21.0
Qualified-buy size	25%	0.833	20.8
Role informativeness (inverted)	20%	0.000	0.0
Recency	10%	0.812	8.1
Buy/sell conviction	10%	1.000	10.0

This is a heuristic ordering under the current rules, not a calibrated return forecast. It explains why candidates rank differently; the public-filing evidence and data limits are shown below.

BULL VS BEAR

Two readings of this buying

The same filings, read two ways. Each line is a fact stored for this company with the number behind it, and appears only when that number crosses a fixed threshold. Neither side is a forecast and no winner is declared.

Since 2026-10-13: new on the bull side: bought in the last two weeks. All bull and bear lists, and what followed each line in the past →

Where the evidence comes from

The two kinds of evidence disagree: the purchases themselves carry bull lines (more buyers than usual here, senior executive buying, bought in the last two weeks), while short sellers argue against (published short positions). Also, company actions point the same way (company is buying back shares).

The insider purchases themselvesBullmore buyers than usual here, senior executive buying, bought in the last two weeks Bearsmall purchases4 checked, under the threshold · 3 missing
Share price and trading2 checked, under the threshold
Short sellersBearpublished short positions
Company results1 checked, under the threshold · 1 missing
Company actionsBullcompany is buying back shares

Bull case · the buying is informative

No insider bought in the 180 days before this window; 4 have bought in it. The buying is new for this company, not a habit.Record: after 3,134 earlier disclosures like this, the median 60-session excess return was −2.7%, within 1 percentage point of all comparable disclosures (−2.7%).
Company actionsThe company announced 4 transactions in its own shares in the last 30 days (latest 2026-10-12); the 4 read are all purchases. The company is buying its own shares while its insiders buy.
The buyers include the CEO or chair, who sees more of the business than most filers. This site's score gives little or no credit for that: in its backtests purchases by senior executives did no better than other insiders' purchases.Record: after 8,797 earlier disclosures like this, the median 60-session excess return was −3.1%, within 1 percentage point of all comparable disclosures (−3.2%).
The latest purchase is 3 days old (2026-10-14). The buying is current, not left over from an earlier quarter.

Bear case · discount it

Net purchases of €379k are <0.01% of the company's market value (€4.8bn): a visible sum, a small one against the business.
Short sellersDisclosed net short positions total 5.15% of the share capital: other professional investors are positioned the opposite way. On 2026-10-02 it was 4.80%: up 0.35 points since.

Evidence still missing

No buyer here has 5 or more completed earlier purchases on record, so there is no track record to weigh.
Only one reading of profitability is held (profit margin 5.0%). Whether earnings and cash flow are rising or falling needs the last two reports side by side.
European notifications have no field saying whether a purchase was pre-arranged; there is no counterpart to the US 10b5-1 box. None of the 4 purchase lines mentions a plan, but a bare “Share purchase” does not rule one out.
The filings give the size of each trade, not what the buyer already held. Whether a purchase added 1% to a personal stake or doubled it is not known.

Checked and under the threshold: 7, 1 close to it

BullAt most 2 insiders bought within any 15 days. Counted for the bull side from 3. close to the threshold
BearThe largest buyer accounts for 35% of the value bought. Counted for the bear side from 80%.
Bear0 of 4 buyers filed as a person closely associated with a manager. Counted for the bear side from half.
BearNo insider sale is recorded in the same 180 days.
BearThe share price changed +7327% over six months (three months +7900%, one month +7980%) and stands 8.2% below its 52-week high. Counted for the bear side from a fall of 20%.
BearOver three months the share price changed +7900% and the median of 271 Healthcare companies changed −6.3%: ahead by 7906 points. Counted for the bear side from 20 points behind.
BearProfit margin on the latest captured figures is 5.0%. Counted for the bear side when negative.

Both columns arrange stored facts only. They do not change the insider score or the ranking and are not investment advice.

Signal history

59.9 / 100

Latest recorded score

↑ +7.7 ptsversus the comparable snapshot on 2026-09-14 (34 calendar days apart)

Recorded snapshots: 35
First snapshot: 2026-08-26

Only scores captured when the scoring run completed are compared. These are raw signal scores saved when each full scoring run completed. They describe changes in research ranking, not price performance or returns.

Why did it change?

Decomposition across the five score factors between comparable snapshots; historical scores are not recalculated.

Purchase size+0.4 pts
Recency+7.4 pts

Signal score history

Fixed 0–100 scale; dates are spaced by calendar time.

Recent recorded points

Aug 26, 202659.1
Sep 7, 202652.6
Sep 28, 202651.8
Oct 7, 202651.6
Oct 18, 202659.9

View all recorded scores

Snapshot date	Signal score
2026-08-26	59.1
2026-08-27	59.1
2026-08-28	53.8
2026-08-31	53.4
2026-09-01	53.2
2026-09-02	53.1
2026-09-03	53.0
2026-09-04	52.9
2026-09-07	52.6
2026-09-08	52.6
2026-09-09	52.5
2026-09-10	52.4
2026-09-11	52.4
2026-09-14	52.2
2026-09-23	51.9
2026-09-24	51.8
2026-09-25	51.8
2026-09-28	51.8
2026-09-29	51.7
2026-09-30	51.7
2026-10-01	51.7
2026-10-02	51.7
2026-10-03	51.7
2026-10-04	51.7
2026-10-05	51.7
2026-10-06	51.7
2026-10-07	51.6
2026-10-08	51.6
2026-10-09	51.6
2026-10-12	51.6
2026-10-13	51.6
2026-10-14	61.8
2026-10-15	61.1
2026-10-16	60.5
2026-10-18	59.9

Sector context

Healthcare

Buying breadth: 6.1% (48 / 792 issuers)
Sector rank: #11 / 12
7D breadth change: -0.4 pp · vs 2026-10-12 (6d)
30D breadth change: History building

This is sector-level research context. It does not affect the Insider Signal or ranking.

View Europe sector research →

Insider profile outcomes

Historical performance following insider filings. The company role is translated below each name while preserving the original title.

Excess return = stock return − FTSE 100 return over the same period.
Hit rate = completed events with positive excess return ÷ total completed events.
Price coverage = valid point-in-time prices ÷ events mature enough for that period.
Returns start on the first shared trading session on or after publication.
Small-sample rule: n<5 is shown for transparency and is not scored.

Events are disclosure-level observations; related disclosures published on the same date may share a return path and may not be statistically independent. This research enrichment does not affect the insider score or ranking.

Fiona RyderChief Financial Officer and PDMR | Interim Chief Financial Officer and PDMR2 completed 20D event(s)

Period	Completed events	Price coverage	Hit rate	Median excess return	Average excess return	Worst excess return
5D	2Small sample	100.0% (2/2)	50.0% (1/2)	+0.2%	+0.2%	-0.4%
20D	2Small sample	100.0% (2/2)	50.0% (1/2)	-1.1%	-1.1%	-5.9%
60D	2Small sample	100.0% (2/2)	50.0% (1/2)	+3.8%	+3.8%	-3.8%
120D	1Small sample	100.0% (1/1)	0.0% (0/1)	-18.8%	-18.8%	-18.8%

First purchase in 12M

1/2

Large purchase ≥ €100k

0/2

Cluster buying · 15D

2/2

Buying the dip · ≥20% below prior 52W high

2/2

Routine / opportunistic

Not classifiable

Jonny MasonChief Executive Officer and PDMR | Interim Chief Executive Officer and PDMR2 completed 20D event(s)

Period	Completed events	Price coverage	Hit rate	Median excess return	Average excess return	Worst excess return
5D	2Small sample	100.0% (2/2)	50.0% (1/2)	+0.2%	+0.2%	-0.4%
20D	2Small sample	100.0% (2/2)	50.0% (1/2)	-1.1%	-1.1%	-5.9%
60D	2Small sample	100.0% (2/2)	50.0% (1/2)	+3.8%	+3.8%	-3.8%
120D	1Small sample	100.0% (1/1)	0.0% (0/1)	-18.8%	-18.8%	-18.8%

First purchase in 12M

1/2

Large purchase ≥ €100k

2/2

Cluster buying · 15D

2/2

Buying the dip · ≥20% below prior 52W high

2/2

Routine / opportunistic

Not classifiable

Tobias HestlerNon-Executive Director2 completed 20D event(s)

Period	Completed events	Price coverage	Hit rate	Median excess return	Average excess return	Worst excess return
5D	2Small sample	100.0% (2/2)	100.0% (2/2)	+1.1%	+1.1%	+0.2%
20D	2Small sample	100.0% (2/2)	0.0% (0/2)	-3.2%	-3.2%	-4.7%
60D	0No data	Awaiting maturity	—	—	—	—
120D	0No data	Awaiting maturity	—	—	—	—

First purchase in 12M

2/2

Large purchase ≥ €100k

2/2

Cluster buying · 15D

0/2

Buying the dip · ≥20% below prior 52W high

0/2

Routine / opportunistic

Not classifiable

Market context

PRICE PERFORMANCE

+7979.7%

+7900.1%

+7327.5%

12M

+7226.0%

VOLATILITY & LIQUIDITY

Volatility: 7312.2%
Beta: 0.77
Avg daily volume: £17.0M

VALUATION

Market cap: £4.0B
P/E: 41.9×

FUNDAMENTALS

Profit margin: 5.0%
ROE: 7.7%
Industry: Medical Instruments & Supplies

Prices to 18 Oct 2026: OpenBB/yfinance. From OpenBB/yfinance, captured 18 Oct 2026: Market cap, P/E, Profit margin, ROE, Beta, Industry. It does not affect the insider score or rank.

Disclosed net short positions

Aggregate net short: 5.15%
Latest position date: 14 Oct 2026

The FCA publishes one aggregate figure per issuer, the sum of all positions notified to it, and does not name the holders. Source: FCA · read 18 Oct 2026

Short-position disclosures are external context; they do not affect the insider score, ranking, or filing eligibility.

Insiders' buying price vs the latest close

Insiders paid 2.14 GBP a share on average (4 purchase lines, 4 buyers, 2026-05-27 – 2026-10-14). The close on 2026-10-16 was 11.3% above that price.

The latest purchase (2026-10-14) was at 2.30 GBP; the close was 3.6% above that price.

Prices paid are weighted by shares and taken from the filings; dividends are not counted. Not scored.

Buying size vs market trading

Quote currency is not verified.

Market-data coverage: 263 verified sessions · Latest session: 2026-10-16 · Ratio status: Unavailable

Recent and largest purchase events / preceding 60-session ADTV

Oct 14 · Jens Viebke · Non-Executive Director
56,071 GBP · —
Quote currency is not verified.
Aug 07 · Tobias Hestler · Non-Executive Director
112,900 GBP · —
Purchase and market currencies differ; ratio withheld.
May 27 · Fiona Ryder · Chief Financial Officer and PDMR
50,004 GBP · —
Purchase and market currencies differ; ratio withheld.
May 27 · Jonny Mason · Chief Executive Officer and PDMR
100,585 GBP · —
Purchase and market currencies differ; ratio withheld.

Traded value is estimated as close × shares traded, in major currency units. Includes disclosed qualifying purchases; disclosures may lag. Contractual or planned acquisitions are not necessarily discretionary. Ratios describe relative trading size, not market participation or score contributions.

Latest news

No news has been captured for this company.

Regulatory filings

Insider filing announcement · published 2026-10-14 · trade date 2026-10-14
Insider filing announcement · published 2026-08-07 · trade date 2026-08-07
Insider filing announcement · published 2026-05-27 · trade date 2026-05-27

Unfold all 5 filings

Insider filing announcement · published 2026-10-14 · trade date 2026-10-14
Insider filing announcement · published 2026-08-07 · trade date 2026-08-07
Insider filing announcement · published 2026-05-27 · trade date 2026-05-27
Insider filing announcement · published 2026-03-17 · trade date 2026-03-17
Insider filing announcement · published 2026-03-12 · trade date 2026-03-11

Filing evidence

These are underlying national-feed records from the 365-day window ending on the saved ranking snapshot. The score uses only the latest 180 days; older qualifying equity purchases remain visible for audit but do not enter the current score. The original filer, role, transaction classification, instrument, price, volume, value and source fields are retained. The first three rows are shown; remaining records can be unfolded for audit. Other transaction types are retained but excluded from the score.

Excluded transactions & classification

4 qualifying purchase disclosure(s) · 4 transaction line(s)

Oct 14, 2026Share purchase

Jens Viebke · Non-Executive Director

Ordinary share of 10p each in Convatec Group Plc · 24400 shares × 2.298 GBP · —

Open filing

Aug 7, 2026Share purchase

Tobias Hestler · Non-Executive Director

Ordinary share of 10p each in Convatec Group Plc · 50000 shares × 2.258 GBP · —

Open filing

May 27, 2026Share purchase

Jonny Mason · Chief Executive Officer and PDMR

Ordinary share of 10p each in Convatec Group Plc · 50000 shares × 2.01169 GBP · —

Open filing

Unfold all 1 remaining filing row(s)

Transaction date	Published	Filer	Role	Transaction	Instrument	Price (local currency)	Quote currency	Volume	Source
2026-05-27	2026-05-27	Fiona Ryder	Chief Financial Officer and PDMR	Share purchase	Ordinary share of 10p each in Convatec Group Plc	2.00071 GBP	GBP	24993	Open filing

Showing 4 of 4 matching raw-feed row(s) from the current 365-day research window. Prices and reported values remain in the filing currency and its major unit (for example, UK pence are parsed as GBP). The screen-level € aggregate is separately FX-normalised for research ranking, not a trade-date conversion.

Other disclosed transactions · excluded from score

View 10 other transaction(s)

Mar 17, 2026a. Vesting of PSA under the LTIP. b. Vesting of RSU under the DBP.

Jonny Mason · Chief Executive Officer and PDMR

Ordinary share of 10p each in Convatec Group Plc · 511469 shares × 0 GBP · —

Open filing

Mar 17, 2026a. Vesting of PSA under the LTIP. b. Vesting of RSU under the DBP.

Jonny Mason · Chief Executive Officer and PDMR

Ordinary share of 10p each in Convatec Group Plc · 106137 shares × 0 GBP · —

Open filing

Mar 17, 2026a. Vesting of PSA under the LTIP. b. Vesting of RSU under the LTIP.

Fiona Ryder · Chief Financial Officer and PDMR

Ordinary share of 10p each in Convatec Group Plc · 27001 shares × 0 GBP · —

Open filing

Unfold all 7 remaining filing row(s)

Transaction date	Published	Filer	Role	Transaction	Instrument	Quote currency	Volume	Source
2026-03-17	2026-03-17	Fiona Ryder	Chief Financial Officer and PDMR	a. Vesting of PSA under the LTIP. b. Vesting of RSU under the LTIP.	Ordinary share of 10p each in Convatec Group Plc	GBP	31748	Open filing
2026-03-11	2026-03-12	Jonny Mason	Chief Executive Officer and PDMR	a. Grant of PSA under the LTIP, subject to performance conditions. b. Grant of DBA under the LTIP, subject to a time-based vesting period of three years. c. Grant of RSA under the LTIP, subject to a time-based vesting period of three years.	Ordinary share of 10p each in Convatec Group Plc	GBP	1776206	Open filing
2026-03-11	2026-03-12	Jonny Mason	Chief Executive Officer and PDMR	a. Grant of PSA under the LTIP, subject to performance conditions. b. Grant of DBA under the LTIP, subject to a time-based vesting period of three years. c. Grant of RSA under the LTIP, subject to a time-based vesting period of three years.	Ordinary share of 10p each in Convatec Group Plc	GBP	165419	Open filing
2026-03-11	2026-03-12	Jonny Mason	Chief Executive Officer and PDMR	a. Grant of PSA under the LTIP, subject to performance conditions. b. Grant of DBA under the LTIP, subject to a time-based vesting period of three years. c. Grant of RSA under the LTIP, subject to a time-based vesting period of three years.	Ordinary share of 10p each in Convatec Group Plc	GBP	417931	Open filing
2026-03-11	2026-03-12	Fiona Ryder	Chief Financial Officer and PDMR	a. Grant of PSA under the LTIP, subject to performance conditions. b. Grant of DBA under the LTIP, subject to a time-based vesting period of three years. c. Grant of RSA under the LTIP, subject to a time-based vesting period of three years.	Ordinary share of 10p each in Convatec Group Plc	GBP	567413	Open filing
2026-03-11	2026-03-12	Fiona Ryder	Chief Financial Officer and PDMR	a. Grant of PSA under the LTIP, subject to performance conditions. b. Grant of DBA under the LTIP, subject to a time-based vesting period of three years. c. Grant of RSA under the LTIP, subject to a time-based vesting period of three years.	Ordinary share of 10p each in Convatec Group Plc	GBP	19028	Open filing
2026-03-11	2026-03-12	Fiona Ryder	Chief Financial Officer and PDMR	a. Grant of PSA under the LTIP, subject to performance conditions. b. Grant of DBA under the LTIP, subject to a time-based vesting period of three years. c. Grant of RSA under the LTIP, subject to a time-based vesting period of three years.	Ordinary share of 10p each in Convatec Group Plc	GBP	170224	Open filing

Showing 10 of 10 matching raw-feed row(s) from the current 365-day research window. Prices and reported values remain in the filing currency and its major unit (for example, UK pence are parsed as GBP). The screen-level € aggregate is separately FX-normalised for research ranking, not a trade-date conversion.

Snapshot & identity

Snapshot date: 2026-10-18
Ticker: CTEC.L
ISIN: GB00BD3VFW73
Sector: Healthcare
Industry: Medical Instruments & Supplies

Company logos by Parqet

Convatec Group Plc

WHY THIS SIGNAL?

Score anatomy

What is holding the score back?

BUYING PROFILE

Buying concentration

Key purchase quotes (filing currency)

Cluster breakdown (does not change the score)

What the filings show

Insider vs stock price

If you had followed the purchase

Insider timeline

This company: insiders buying per month, last 12 months

Who traded

Two readings of this buying

Where the evidence comes from

Bull case · the buying is informative

Bear case · discount it

Evidence still missing

Signal score history

Recent recorded points

Sector context

Insider profile outcomes

Market context

PRICE PERFORMANCE

VOLATILITY & LIQUIDITY

VALUATION

FUNDAMENTALS

Disclosed net short positions

Insiders' buying price vs the latest close

Buying size vs market trading

Recent and largest purchase events / preceding 60-session ADTV

Latest news

Regulatory filings

Filing evidence

Other disclosed transactions · excluded from score

Snapshot & identity

Share this page